RAPA-Keloid Study of Keloid Regression

NCT ID: NCT04049552

Last Updated: 2021-09-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-24

Study Completion Date

2021-05-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. To test whether topical rapamycin regresses established keloids in humans by measuring surface area and height changes in the scar over time (6 months)
2. To test safety of product and feasibility of conduct for future clinical trial

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This pilot trial will use daily 0.5-1.0 ml applications of 8% RAPA (Rapamycin) in a petrolatum vehicle to treat established keloid lesions in 5 persons with at least 2 chronic keloids in similar body regions (greater than 1-year duration). Treatment will be applied once daily for 6 months. One keloid will receive 8% RAPA ointment and the other keloid will receive petrolatum-only ointment as a control. Surface areas and height of keloids will be monitored pre- and post-treatment to evaluate responses.

Keloid surface area and height changes will be measured pre-treatment and thereafter on a monthly basis using standardized digital photography with a tripod-mounted 8MP Canon S5is camera and calipers to measure keloid height (37).

Surface areas of all photographed lesions will be measured with Image J (http://rsbweb.nih.gov/ij/index.html), a public image-processing program that was used to analyze preliminary data and this study will use the same approach.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Keloid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Study participants will serve as their own control, using intervention on one keloid and placebo on the other
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RAPA intervention

Rapamycin ointment will be applied to one keloid on the subject

Group Type EXPERIMENTAL

Rapamycin 8% Ointment

Intervention Type DRUG

A compounded ointment containing 8% rapamycin

Placebo

Placebo will be applied as a control on one keloid on the subject

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Petrolatum ointment placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rapamycin 8% Ointment

A compounded ointment containing 8% rapamycin

Intervention Type DRUG

Placebo

Petrolatum ointment placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Rapamycin ointment Petrolatum ointment

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject must have at least 2 keloid scars (for at least 1 year) in similar body locations that are easy to reach to apply ointment to
* Subject will be in good health with all chronic diseases (such as hypertension, coronary artery disease, etc.) clinically stable
* Cognitive functioning sufficient to provide informed consent
* Physically able to apply ointment to keloids daily
* Able to attend monthly clinic visits for 6 months

Exclusion Criteria

* Diagnosis of diabetes
* Subjects taking the following medications: systemic steroid or immunosuppressant therapy within the past 6 months
* Local area steroidal treatment within the past 3 months
* History of allergy to rapamycin of petrolatum-based products
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The University of Texas Health Science Center at San Antonio

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dean L Kellogg Jr, MD

Role: PRINCIPAL_INVESTIGATOR

UT Health San Antonio

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Audie L Murphy Memorial Veterans Hospital

San Antonio, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HSC20190291H

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Daily Topical Rapamycin for Vitiligo
NCT05342519 ACTIVE_NOT_RECRUITING PHASE2
Topical Rapamycin for Fibrofolliculomas
NCT00928798 COMPLETED PHASE3